{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-008611","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.474018+00:00","generated_at":"2026-05-15T10:04:50.120386+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"CervoMed Q4/FY2025 net loss widens to $27M; cash runway ~6 months; Phase 3 DLB trial pending financing","bullets":["FY2025 net loss $27.0M vs $16.2M; cash $20.9M (down from $38.9M), sufficient for ~6 months.","FDA alignment obtained for planned Phase 3 DLB trial; initiation in H2 2026 subject to funding.","Selected 50mg TID neflamapimod dose for Phase 3; additional data to be presented at AD/PD 2026.","Topline data expected H2 2026 from Phase 2a RAS and nfvPPA trials; ALS trial start by YE 2026.","Grant revenue fell to $4.0M from $9.7M due to RewinD-LB completion; R&D spend rose to $21.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-008611","json":"https://secwatch.observer/filing/0001437749-26-008611.json","markdown":"https://secwatch.observer/filing/0001437749-26-008611.md","text":"https://secwatch.observer/filing/0001437749-26-008611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/0001437749-26-008611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/crvo20260317_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:04:50.120386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}